Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1816MR)

This product GTTS-WQ1816MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1816MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5986MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ4612MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ5387MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ8855MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ3491MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ11468MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ6917MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ1689MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW